AstraZeneca and Daiichi Sankyo's ENHERTU plus pertuzumab showed a median progression-free survival greater than three years (10642.0000p, -78)
Daiichi Sankyo presents positive results from three trials of DATROWAY in patients with early and advanced non-small cell lung cancer (¥3842.0000, 0)
Daiichi Sankyo announces positive results from DESTINY-Gastric04 phase 3 trial of ENHERTU as second-Line therapy in patients with HER2 positive unresectable or metastatic gastric cancer (¥3842.0000, 0)
StreetAccount Sector Summary - Healthcare Post-Market
StreetAccount Sector Summary - Healthcare Pre-Market
Daiichi Sankyo, Merck voluntarily withdraw BLA for patritumab deruxtecan for patients with previously treated locally advanced or metastatic EGFR-mutated NSCLC (¥3894.0000, 0)
AstraZeneca's ENHERTU (trastuzumab deruxtecan) receives time-limited reimbursement recommendation from Canada's Drug Agency for gastric cancer (10358.0000p, -16)
NTK files motion to expand claims in lawsuit for compensation for damages against Daiichi Sankyo (¥3753.0000, 0)
Daiichi Sankyo doses first patient in phase III trial of ifinatamab deruxtecan for treatment of pretreated advanced or metastatic esophageal squamous cell carcinoma (¥3698.0000, 0)
StreetAccount Summary - Trading higher/lower: Asia mid-morning
Powered by FactSet Research Systems Inc.